Lisata Therapeutics shares are trading higher after the company announced its first patient was treated in the second-line cholangiocarcinoma cohort of the BOLSTER trial.
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics shares rose following the announcement that the first patient was treated in the second-line cholangiocarcinoma cohort of the BOLSTER trial.
September 17, 2024 | 6:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics shares increased after the company announced the treatment of the first patient in the BOLSTER trial's second-line cholangiocarcinoma cohort.
The initiation of patient treatment in a clinical trial is a significant milestone for biotech companies, often leading to positive investor sentiment and a rise in stock price. This development suggests progress in Lisata's clinical pipeline, which is likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100